Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Study to Assess the Safety of Pertagen®, a Recombinant Acellular Pertussis Vaccine in Pregnant Women in Thailand

NCT06888076 is registered in ClinicalTrials.gov with BioNet-Asia Co., Ltd. as lead sponsor.

NCT NCT06888076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06888076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Study to Assess the Safety of Pertagen®, a Recombinant Acellular Pertussis Vaccine in Pregnant Women in Thailand
Lead sponsor
BioNet-Asia Co., Ltd.
Phase
Observational
Overall status
Active, not recruiting
Start date
December 12, 2024
Completion date
October 31, 2025
Enrollment
2,700 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pertussis (whooping cough), pertussis vaccines